Tonix Pharmaceuticals Holding Corp (TNXP) FinancialsTNXPTonix Pharmaceuticals Holding Corp

Evaluating the bottom line, Tonix Pharmaceuticals Holding Corp. maintains a gross margin of 94.81%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -314.05%, while the net margin is -299.41%. These profitability ratios, combined with a Return on Equity (ROE) of -81.82%, provide a clear picture of how effectively TNXP converts its operational activities into shareholder value.

In the context of the broader market, TNXP competes directly with industry leaders such as MIST and TNYA. With a market capitalization of $78.89M, it holds a significant position in the sector. When comparing efficiency, TNXP's gross margin of 94.81% stands against MIST's 94.28% and TNYA's N/A. Such benchmarking helps identify whether Tonix Pharmaceuticals Holding Corp. is trading at a premium or discount relative to its financial performance.

Tonix Pharmaceuticals has demonstrated significant revenue growth, with Q2 2026 net product revenue of $13.54 million, a substantial increase from $2 million in Q2 2025. The gross margin has also improved to 94.81%, indicating better cost management and profitability potential.